223 related articles for article (PubMed ID: 18626312)
1. Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma.
Hauschild A; Trefzer U; Garbe C; Kaehler KC; Ugurel S; Kiecker F; Eigentler T; Krissel H; Schott A; Schadendorf D
Melanoma Res; 2008 Aug; 18(4):274-8. PubMed ID: 18626312
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
Daud AI; Dawson J; DeConti RC; Bicaku E; Marchion D; Bastien S; Hausheer FA; Lush R; Neuger A; Sullivan DM; Munster PN
Clin Cancer Res; 2009 Apr; 15(7):2479-87. PubMed ID: 19318485
[TBL] [Abstract][Full Text] [Related]
3. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
Wyman K; Atkins MB; Prieto V; Eton O; McDermott DF; Hubbard F; Byrnes C; Sanders K; Sosman JA
Cancer; 2006 May; 106(9):2005-11. PubMed ID: 16565971
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma.
Eisen T; Thomas J; Miller WH; Gore M; Wolter P; Kavan P; Martín JA; Lardelli P
Melanoma Res; 2009 Jun; 19(3):185-92. PubMed ID: 19436178
[TBL] [Abstract][Full Text] [Related]
5. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas.
Gore L; Rothenberg ML; O'Bryant CL; Schultz MK; Sandler AB; Coffin D; McCoy C; Schott A; Scholz C; Eckhardt SG
Clin Cancer Res; 2008 Jul; 14(14):4517-25. PubMed ID: 18579665
[TBL] [Abstract][Full Text] [Related]
6. Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
Eisen T; Trefzer U; Hamilton A; Hersey P; Millward M; Knight RD; Jungnelius JU; Glaspy J
Cancer; 2010 Jan; 116(1):146-54. PubMed ID: 19862820
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo therapy of malignant melanomas transplanted into organotypic brain slice cultures using inhibitors of histone deacetylases.
Hölsken A; Eyüpoglu IY; Lueders M; Tränkle C; Dieckmann D; Buslei R; Hahnen E; Blümcke I; Siebzehnrübl FA
Acta Neuropathol; 2006 Aug; 112(2):205-15. PubMed ID: 16773328
[TBL] [Abstract][Full Text] [Related]
8. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
McDermott DF; Sosman JA; Gonzalez R; Hodi FS; Linette GP; Richards J; Jakub JW; Beeram M; Tarantolo S; Agarwala S; Frenette G; Puzanov I; Cranmer L; Lewis K; Kirkwood J; White JM; Xia C; Patel K; Hersh E
J Clin Oncol; 2008 May; 26(13):2178-85. PubMed ID: 18445842
[TBL] [Abstract][Full Text] [Related]
9. Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma.
Glaspy J; Atkins MB; Richards JM; Agarwala SS; O'Day S; Knight RD; Jungnelius JU; Bedikian AY
Cancer; 2009 Nov; 115(22):5228-36. PubMed ID: 19728370
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.
Ryan QC; Headlee D; Acharya M; Sparreboom A; Trepel JB; Ye J; Figg WD; Hwang K; Chung EJ; Murgo A; Melillo G; Elsayed Y; Monga M; Kalnitskiy M; Zwiebel J; Sausville EA
J Clin Oncol; 2005 Jun; 23(17):3912-22. PubMed ID: 15851766
[TBL] [Abstract][Full Text] [Related]
11. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R
Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
[TBL] [Abstract][Full Text] [Related]
12. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
[TBL] [Abstract][Full Text] [Related]
13. A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma.
Kirkwood JM; Gonzalez R; Reintgen D; Clingan PR; McWilliams RR; de Alwis DP; Zimmermann A; Brown MP; Ilaria RL; Millward MJ
Cancer; 2011 Oct; 117(20):4732-9. PubMed ID: 21456002
[TBL] [Abstract][Full Text] [Related]
14. A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma.
Hamid O; Ilaria R; Garbe C; Wolter P; Maio M; Hutson TE; Arance A; Lorigan P; Lee J; Hauschild A; Mohr P; Hahka-Kemppinen M; Kaiser C; Turner PK; Conti I; Grob JJ
Cancer; 2014 Jul; 120(13):2016-24. PubMed ID: 24676877
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of arsenic trioxide in patients with metastatic melanoma.
Kim KB; Bedikian AY; Camacho LH; Papadopoulos NE; McCullough C
Cancer; 2005 Oct; 104(8):1687-92. PubMed ID: 16130126
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.
Eisen T; Thatcher N; Leyvraz S; Miller WH; Couture F; Lorigan P; Lüthi F; Small D; Tanovic A; O'Brien M
Lung Cancer; 2009 Apr; 64(1):60-5. PubMed ID: 18692272
[TBL] [Abstract][Full Text] [Related]
17. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.
Münster P; Marchion D; Bicaku E; Schmitt M; Lee JH; DeConti R; Simon G; Fishman M; Minton S; Garrett C; Chiappori A; Lush R; Sullivan D; Daud A
J Clin Oncol; 2007 May; 25(15):1979-85. PubMed ID: 17513804
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
[TBL] [Abstract][Full Text] [Related]
20. Bleomycin, vinorelbine and trofosfamide in relapsed stage IV cutaneous malignant melanoma patients.
Atzpodien J; Morawek L; Fluck M; Reitz M
Cancer Chemother Pharmacol; 2009 Oct; 64(5):901-5. PubMed ID: 19229537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
